NCT05972577Completed
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Optimization of Older Adult Allogeneic Hematopoietic Cell Transplant Candidates to Improve Survival (OTIS)
Source: ClinicalTrials.gov · Last updated 6 Apr 2026
Brief summary (registry, in English)
This clinical trial tests whether a geriatric optimization plan (GO!) works to improve survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplant. GO! focuses on creating a tailored and specific plan for each patient to make changes in their daily lives. These may include changes to their diet, sleep, activity, medicines, or even referrals to other providers depending on the patient's needs. Studying survival and quality of life in patients over 60 receiving an allogeneic hematopoietic cell transplant may help identify the effects of treatment.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 13 Jul 2022
- Start date
- 11 Jun 2021
- Primary completion date
- 13 Nov 2024
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Diseases
- Acute lymphoblastic leukaemia, Myeloproliferative neoplasms, Hodgkin lymphoma, Chronic myeloid leukaemia, Myelodysplastic syndromes, Chronic lymphocytic leukaemia, Multiple myeloma, Acute myeloid leukemia
- NCT number
- NCT05972577
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From 11 Jun 2021 to the primary completion date, 13 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- No possibility of proceeding to allogeneic hematopoietic cell transplant within the next 6 months as determined by treating physician
- Scheduled admission for allogeneic hematopoietic cell transplant within 30 days of enrollment
Other illness
- Documented history of dementia
Other
- Inability or unwillingness to give written informed consent
Who the study is looking for
- Age \>= 60 years
- Diagnosed with hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplantation. This includes acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelofibrosis, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, and aplastic anemia. Disease specific eligibility for allo-HCT to be determined by treating physician
- Must be able to understand written and spoken English
- Must be willing to attend all study visits and comply with study procedures for the entire length of the study
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ohio State University Comprehensive Cancer Center Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.